Janux Therapeutics (JANX) Amortizatization of Intangibles (2021 - 2026)
Janux Therapeutics (JANX) posted quarterly Amortizatization of Intangibles of $2.6 million for Q1 2026, down 37.83% year-over-year from $4.2 million in Q1 2025, and down 25.54% quarter-over-quarter from $3.5 million in Q4 2025.
Janux Therapeutics (JANX) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Amortizatization of Intangibles for 6 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 37.83% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $16.0 million (up 22.72% YoY), while the FY2025 annual figure was $17.6 million, up 66.03% from the prior year.
- Amortizatization of Intangibles declined to $2.6 million in Q1 2026 per JANX's latest filing, from $3.5 million in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $5.2 million in Q2 2025 and bottomed at $24000.0 in Q1 2022.
- Historically, Amortizatization of Intangibles has averaged $2.4 million across 5 years, with a median of $2.1 million in 2023.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles surged 6891.67% — and 2026, when it tumbled 37.83%.
- Janux Therapeutics' Amortizatization of Intangibles stood at $1.3 million in 2022, then jumped by 59.52% to $2.1 million in 2023, then surged by 42.02% to $2.9 million in 2024, then climbed by 20.4% to $3.5 million in 2025, then fell by 25.54% to $2.6 million in 2026.
- Business Quant data shows JANX's Amortizatization of Intangibles at $2.6 million in Q1 2026, $3.5 million in Q4 2025, and $4.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.33 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 678,000.00 |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | 2.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.89 Mn |
| Jun 30, 2026 | 2.89 Mn |
| Mar 31, 2026 | 2.62 Mn |
| Mar 31, 2026 | 2.62 Mn |
| Dec 31, 2025 | 3.52 Mn |
| Dec 31, 2025 | 3.52 Mn |
| Sep 30, 2025 | 4.62 Mn |
| Sep 30, 2025 | 4.62 Mn |
| Jun 30, 2025 | 5.21 Mn |
| Jun 30, 2025 | 5.21 Mn |
| Mar 31, 2025 | 4.22 Mn |
| Mar 31, 2025 | 4.22 Mn |
| Dec 31, 2024 | 2.93 Mn |
| Dec 31, 2024 | 2.93 Mn |
| Sep 30, 2024 | 2.90 Mn |
| Sep 30, 2024 | 2.90 Mn |
| Jun 30, 2024 | 2.97 Mn |
| Jun 30, 2024 | 2.97 Mn |
| Mar 31, 2024 | 1.79 Mn |
| Mar 31, 2024 | 1.79 Mn |